Wedbush Reiterates Buy Rating on Viridian Therapeutics
Wedbush keeps its buy rating for Viridian Therapeutics, setting a $43 price target, a 134.08% upside from the current price.
Key Points
- On June 30, 2026, Wedbush reiterated its buy rating on Viridian Therapeutics (NasdaqCM: VRDN) with a price target of $43.
- Wedbush's $43 price target implies 134.08% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
- Shares of Viridian Therapeutics traded at $18.79 on Wednesday, with a market cap of approximately $2.03 billion.
- Analysts maintain a strong buy consensus for Viridian, with a mean price target of $35.5 among 16 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Wedbush analyst Laura Chico reiterated her buy rating on Viridian Therapeutics, Inc. (NasdaqCM: VRDN), maintaining a price target of $43. This news comes as the company's shares traded near $18.79 on Wednesday.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On the same day, RBC Capital and Truist Securities also maintained their buy ratings on Viridian Therapeutics, with price targets of $35 and $38, respectively. Needham joined the chorus with a buy rating and a $34 target. Meanwhile, Wells Fargo upgraded its rating to buy on June 29, setting a $31 target. The consensus among analysts remains strong buy, with an average price target of $35.5 based on 16 analyst opinions.
Viridian Therapeutics, Inc. Stock Down 20.4%
Shares of Viridian Therapeutics traded at $18.79 on Wednesday. The biotechnology company, with a market cap of about $2.03 billion, is not currently profitable, resulting in no meaningful P/E ratio. The stock's 52-week range spans from $13.18 to $34.29, with a 50-day moving average of $16.21 and a 200-day moving average of $24.11. Viridian's beta is 0.902, indicating moderate volatility compared to the market.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Fairmount Funds Management LLC purchased 1,176,470 shares at an average price of $17 on May 11, 2026. On March 3, 2026, several insiders, including Chief Legal Officer Jennifer Tousignant and CEO Stephen Mahoney, sold shares at an average price of $30.19. Tousignant also bought 5,169 shares on the same day.
About Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for serious and rare diseases, particularly thyroid eye disease and Graves' disease. The company is led by CEO Stephen F. Mahoney and employs 252 people. Viridian's portfolio includes innovative therapies like Veligrotrug and Elegrobart, targeting IGF-1R for intravenous and subcutaneous administration, respectively.
Bottom Line
Wedbush's reiteration of its buy rating and the $43 target reflects ongoing confidence in Viridian Therapeutics' potential. Analysts widely agree on the stock's prospects, with a strong buy consensus. As always, it's important to remember that analyst ratings are just one piece of the puzzle. Investors should consider multiple factors when evaluating a stock's potential.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.